$8.98
0.627.42%
Last update: Nov 9, 9:01 AM
Harvard Bioscience Inc
HBIONASDAQ
Harvard Bioscience (HBIO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Harvard Bioscience (HBIO) last issued guidance on August 11, 2026 for fiscal year 2026. The company guided revenue in the range of $89.15M - $90.88M for the period.
Compared to prior guidance, Harvard Bioscience raised its revenue forecast from a prior range of $21M - $22.6M.
Harvard Bioscience has issued 15 guidance updates between August 8, 2023 and August 11, 2026. During this period, the company raised its outlook 4 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.15 | $-0.03 | $0.30 | $0.10 |
| Actual | $-0.14 | $-0.33 | $0.00 | $0.00 |
| Surprise | +6.67% | -1000.0% | -100.0% | -100.0% |
| Revenue | ||||
| Estimate | $21.4M | $21.2M | $23.1M | $20.0M |
| Actual | $22.7M | $20.8M | $23.7M | $20.6M |
| Surprise | +5.95% | -2.10% | +2.75% | +2.95% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.27 | $0.11 | $-0.37 | $-0.34 |
| Revenue | ||||
| Consensus | $21.8M | $24.5M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.14 | $-0.15 | 6.67 % |
| Q1 | May 12, 2026 | $-0.33 | $-0.03 | -1000.0 % |
| Q4 | Mar 12, 2026 | $0 | $0.30 | -100.0 % |
| Q3 | Nov 6, 2025 | $0 | $0.10 | -100.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $22.73M | $21.45M | 5.95 % |
| Q1 | May 12, 2026 | $20.76M | $21.20M | -2.10 % |
| Q4 | Mar 12, 2026 | $23.74M | $23.10M | 2.75 % |
| Q3 | Nov 6, 2025 | $20.59M | $20.00M | 2.95 % |
